These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 36168594)

  • 1. Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review.
    Yee KS; Alexanderian D; Feng Y; Ren X; Schweikert B; Ayodele O
    J Health Econ Outcomes Res; 2022; 9(2):67-76. PubMed ID: 36168594
    [No Abstract]   [Full Text] [Related]  

  • 2. Clinical Characteristics and Healthcare Resource Utilization for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review.
    Ayodele O; Müller K; Setayeshgar S; Alexanderian D; Yee KS
    J Health Econ Outcomes Res; 2022; 9(1):117-127. PubMed ID: 35620452
    [No Abstract]   [Full Text] [Related]  

  • 3. Evaluation of the long-term treatment effects of intravenous idursulfase in patients with mucopolysaccharidosis II (MPS II) using statistical modeling: data from the Hunter Outcome Survey (HOS).
    Muenzer J; Botha J; Harmatz P; Giugliani R; Kampmann C; Burton BK
    Orphanet J Rare Dis; 2021 Oct; 16(1):456. PubMed ID: 34717704
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Development of idursulfase therapy for mucopolysaccharidosis type II (Hunter syndrome): the past, the present and the future.
    Whiteman DA; Kimura A
    Drug Des Devel Ther; 2017; 11():2467-2480. PubMed ID: 28860717
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of the clinical outcomes in idursulfase-treated and untreated Filipino patients with mucopolysaccharidosis type II: data from the local lysosomal storage disease registry.
    Racoma MJC; Calibag MKKB; Cordero CP; Abacan MAR; Chiong MAD
    Orphanet J Rare Dis; 2021 Jul; 16(1):323. PubMed ID: 34289859
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Caregiver experiences and observations of intrathecal idursulfase-IT treatment in a phase 2/3 trial in pediatric patients with neuronopathic mucopolysaccharidosis II.
    Yee KS; Lewis S; Evans E; Romano C; Alexanderian D
    Orphanet J Rare Dis; 2024 Mar; 19(1):110. PubMed ID: 38462612
    [TBL] [Abstract][Full Text] [Related]  

  • 7. First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: case observations from the Hunter Outcome Survey (HOS).
    Alcalde-Martín C; Muro-Tudelilla JM; Cancho-Candela R; Gutiérrez-Solana LG; Pintos-Morell G; Martí-Herrero M; Munguira-Aguado P; Galán-Gómez E
    Eur J Med Genet; 2010; 53(6):371-7. PubMed ID: 20709629
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enzymatic replacement therapy for Hunter disease: Up to 9 years experience with 17 patients.
    Parini R; Rigoldi M; Tedesco L; Boffi L; Brambilla A; Bertoletti S; Boncimino A; Del Longo A; De Lorenzo P; Gaini R; Gallone D; Gasperini S; Giussani C; Grimaldi M; Grioni D; Meregalli P; Messinesi G; Nichelli F; Romagnoli M; Russo P; Sganzerla E; Valsecchi G; Biondi A
    Mol Genet Metab Rep; 2015 Jun; 3():65-74. PubMed ID: 26937399
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy.
    Wraith JE; Scarpa M; Beck M; Bodamer OA; De Meirleir L; Guffon N; Meldgaard Lund A; Malm G; Van der Ploeg AT; Zeman J
    Eur J Pediatr; 2008 Mar; 167(3):267-77. PubMed ID: 18038146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing is everything: Clinical courses of Hunter syndrome associated with age at initiation of therapy in a sibling pair.
    Grant N; Sohn YB; Ellinwood NM; Okenfuss E; Mendelsohn BA; Lynch LE; Braunlin EA; Harmatz PR; Eisengart JB
    Mol Genet Metab Rep; 2022 Mar; 30():100845. PubMed ID: 35242576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study.
    Guffon N; Heron B; Chabrol B; Feillet F; Montauban V; Valayannopoulos V
    Orphanet J Rare Dis; 2015 Apr; 10():43. PubMed ID: 25887606
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Divergent developmental trajectories in two siblings with neuropathic mucopolysaccharidosis type II (Hunter syndrome) receiving conventional and novel enzyme replacement therapies: A case report.
    Tomita K; Okamoto S; Seto T; Hamazaki T; So S; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
    JIMD Rep; 2021 Nov; 62(1):9-14. PubMed ID: 34765392
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Therapy-type related long-term outcomes in mucopolysaccaridosis type II (Hunter syndrome) - Case series.
    Zerjav Tansek M; Kodric J; Klemencic S; Boelens JJ; van Hasselt PM; Drole Torkar A; Doric M; Koren A; Avcin S; Battelino T; Groselj U
    Mol Genet Metab Rep; 2021 Sep; 28():100779. PubMed ID: 34258227
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic Options for Mucopolysaccharidosis II (Hunter Disease).
    Kubaski F; Vairo F; Baldo G; de Oliveira Poswar F; Corte AD; Giugliani R
    Curr Pharm Des; 2020; 26(40):5100-5109. PubMed ID: 33138761
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II.
    Wang RY; Cambray-Forker EJ; Ohanian K; Karlin DS; Covault KK; Schwartz PH; Abdenur JE
    Mol Genet Metab; 2009 Dec; 98(4):406-11. PubMed ID: 19748810
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term experience with idursulfase beta (Hunterase) in two adolescent patients with MPS II: A case series.
    Chan MY; Nelson AJ; Ngu LH
    Mol Genet Metab Rep; 2023 Sep; 36():100991. PubMed ID: 37670899
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of idursulfase enzyme replacement therapy for Mucopolysaccharidosis type II when started in early infancy: comparison in two siblings.
    Tajima G; Sakura N; Kosuga M; Okuyama T; Kobayashi M
    Mol Genet Metab; 2013 Mar; 108(3):172-7. PubMed ID: 23375472
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: A case report.
    Kim S; Whitley CB; Jarnes Utz JR
    Mol Genet Metab; 2017 Sep; 122(1-2):92-99. PubMed ID: 28610913
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.